Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has informed the Bombay Stock Exchange that the Statement of Deviation or Variation under SEBI's Listing Regulations is not applicable for the quarter ended 30 June 2025. This is because the company did not raise any money through a public issue, rights issue, preferential issue, or Qualified Institutions Placement during the quarter. The filing was made in non-XBRL format as the XBRL portal does not allow NIL entries. The letter is signed by Dr K Koteswara Rao, Chairman and Managing Director.
This is a routine compliance disclosure with no material impact on shareholders or the stock price — no funds were raised, so there is no deviation or variation to report.